Endocrinology, diabetes and metabolism journal最新文献_第8页

Is Metformin a Drug or a Buffer and why is this Significant? Further Evidence that the Brain Regulates the Autonomic Nervous System, in Particular Prevailing Levels of Intercellular pH 二甲双胍是药物还是缓冲剂?为什么这很重要?进一步的证据表明，大脑调节自主神经系统，特别是细胞间pH值的普遍水平

Endocrinology, diabetes and metabolism journal Pub Date : 2018-11-10 DOI: 10.31038/edmj.2018243

G. Ewing

{"title":"Is Metformin a Drug or a Buffer and why is this Significant? Further Evidence that the Brain Regulates the Autonomic Nervous System, in Particular Prevailing Levels of Intercellular pH","authors":"G. Ewing","doi":"10.31038/edmj.2018243","DOIUrl":"https://doi.org/10.31038/edmj.2018243","url":null,"abstract":"This paper builds upon a body of research which illustrates that the main function of the brain is to modulate the coherent function of the organ networks more commonly known as physiological systems and hence ensure our optimum physiological stability and function. The aim of this article is to further develop this hypothesis and illustrate examples which support it. Moreover the existence of the neurological paradigm i.e. the mechanism by which the brain regulates the coherent function of the physiological systems, by comparison to the contemporary biological paradigm, illustrates fundamental conceptual limitations of biomedicine and, in particular, of the most widely used diabetes drug metformin; in particular that at normal dosage metformin does not appear to function as a drug but instead as a biological buffer which regulates plasma pH at indicatively 6.9–7.1 thereby adversely changing plasma pH to a level which, for many, ensures that their diabetes persists for as long as they are taking this medication and which for the obese may defer the progression of more severe diabetic comorbidities. Such an observation requires a fundamental rethink of what exactly is diabetes and has significant implications re what is diabetes, how it should be measured, and how it should be treated i.e. by dealing with the neurological origins of the condition or by treating the biomedical consequences, or by a combination of both approaches.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47141174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

The Past, Present, and Future of Pancreas Transplantation for Diabetes Mellitus 胰腺移植治疗糖尿病的过去、现在和未来

Endocrinology, diabetes and metabolism journal Pub Date : 2018-09-27 DOI: 10.31038/edmj.2018235

R. Stratta, A. Gruessner, R. Stratta

{"title":"The Past, Present, and Future of Pancreas Transplantation for Diabetes Mellitus","authors":"R. Stratta, A. Gruessner, R. Stratta","doi":"10.31038/edmj.2018235","DOIUrl":"https://doi.org/10.31038/edmj.2018235","url":null,"abstract":"Pancreas transplantation was initially developed as a means to reestablish endogenous insulin secretion responsive to normal feedback controls and has evolved over time to a form of auto-regulating total pancreatic endocrine replacement therapy that can reliably achieve a durable euglycemic state without the need for either exogenous insulin therapy or close glucose monitoring. Pancreas transplantation is performed in patients who require administration of insulin because of type 1 or, less commonly, insulin-requiring type 2 diabetes, or following total pancreatectomy for benign disease [1]. Pancreas transplantation entails a major surgical procedure and the necessity for long-term immunosuppression so it is not offered universally to all patients with insulin-requiring diabetes but is usually directed to those that will already be committed to chronic immunosuppression [most commonly for kidney transplantation secondary to end stage diabetic nephropathy) [1]. In addition, candidates with potentially life-threatening metabolic complications from diabetes such as hypoglycemia unawareness or those who are failures of exogenous insulin therapy may benefit from pancreas transplantation in the absence of a kidney transplant [2]. A successful pancreas transplant is currently the only definitive long-term treatment that restores normal glucose homeostasis in patients with complicated diabetes without the risk of either severe hypo/hyperglycemia and may prevent, stabilize, or reverse progressive diabetic complications [1–3].","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47392887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Serum 25-hydroxyvitamin D and Osteocalcin Levels and Insulin Sensitivity in Young Women 年轻女性血清25-羟基维生素D和骨钙素水平与胰岛素敏感性

Endocrinology, diabetes and metabolism journal Pub Date : 2018-09-27 DOI: 10.31038/edmj.2018241

송도경

引用次数: 0

Plasma Visfatin is reduced in Subjects with the Metabolic Syndrome and Pre-Diabetes 代谢综合征和糖尿病前期患者血浆内脂素降低

Endocrinology, diabetes and metabolism journal Pub Date : 2018-09-27 DOI: 10.31038/edmj.2018234

Brema, Gasparro, Crowley, Storka, J. Nolan

{"title":"Plasma Visfatin is reduced in Subjects with the Metabolic Syndrome and Pre-Diabetes","authors":"Brema, Gasparro, Crowley, Storka, J. Nolan","doi":"10.31038/edmj.2018234","DOIUrl":"https://doi.org/10.31038/edmj.2018234","url":null,"abstract":"The adipocytokine Visfatin (VF) has been linked with visceral adiposity, insulin resistance and Metabolic Syndrome (MS), however, studies have been inconsistent regarding its relationship with these metabolic enteties. The aim of this study was to explore the relationships between plasma VF, High Molecular Weight (HMW) Adiponectin and the MS. We measured fasting plasma VF and HMW Adiponectin in 29 males with the MS and 29 age-matched male controls. Plasma VF was significantly reduced in MS subjetcs compared to controls (98.2 ± 29.7 Vs.141.4 ± 39.1 ng/ml, respectively, P=0.04). One Way ANOVA showed that subjects with MS and pre-diabetes had extremely lower concentrations of plasma VF (60.8 ± 35.9 Vs141.4 ± 39.1 ng/ml ), for MS and controls, respectively, P < 0.009. HMW Adiponectin concentrations were similar in both groups and negatively correlated with HOMA-IR(r = -0.40, P= 0.03). Using Stepwise regression, WC was independently associated with plasma VF concentrations. There was no correlation between plasma VF and insulin sensitivty or beta cell function measured with HOMA-IR and HOMA % B, respectively. In conclusion: Reduced plasma VF concentrations may play a role in the pathophysiology of pre-diabetes and cardiometabolic risk, however, this will require further study.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42049895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. 口服糖尿病药物的持久性:到达A1c基线的时间和初级保健提供者常用口服药物的回顾。

Endocrinology, diabetes and metabolism journal Pub Date : 2018-09-01 Epub Date: 2018-07-08

Lavanya Cherukuri, Michael S Smith, John A Tayek

{"title":"The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider.","authors":"Lavanya Cherukuri, Michael S Smith, John A Tayek","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Cost of generic medications has risen more in the past few years than any other time in history. While medical insurance covers much of these costs, health care professionals can better provide medications that have the longest duration of action when compared to placebo-treated controls. This will save health care costs and improve prescribing accuracy.Methods: Papers in PubMed were identified with keywords placebo. The study must be at least 2 years in length to evaluate the change in A1c over time. The primary endpoint was time to A1c neutrality (return of A1c to baseline at a maximum dose of single oral agent). A medication would be considered at neutrality if the 95% CI crossed baseline. Time to neutrality was averaged for each medication within the class and each summarized for class effect.Results: Effective therapy for the DPP-4 and sulfonylurea classes of medications are 3-4 years as compared to a 5-year time to A1c neutrality for metformin usage. In comparison, the projected time to A1c neutrality was approximately 6-8 years for rosiglitazone and pioglitazone. While only a few studies have been published in the SGLT-2 class of medication, the time to A1c neutrality was also 6-8 years with Canagliflozin and full dosage of Empagliflozin.Conclusion: Metformin appears to have a 5-year duration of effect before the A1c returns to baseline. The sulfonylureas and DPP-4 inhibitors class of medications have one of the shortest durability which ranges between 3.3 to 4.4 years. In contrast, the SGLT-2 class of medication and the TZD class of medications has a projected time to A1c neutrality from 6-8 years. Diabetic duration of therapy as compared to placebo should be listed with those medications tested so the provider can choose wisely.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200420/pdf/nihms-989745.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36669380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improvement in Bone Density with Calcitriol Substitution for Cholecalciferol in Refractory Osteoporosis induced by Prednisone 骨化三醇替代胆钙化醇改善泼尼松诱导的难治性骨质疏松症的骨密度

Endocrinology, diabetes and metabolism journal Pub Date : 2018-08-27 DOI: 10.31038/edmj.2018233

U. Kabadi, Salina Esmail

{"title":"Improvement in Bone Density with Calcitriol Substitution for Cholecalciferol in Refractory Osteoporosis induced by Prednisone","authors":"U. Kabadi, Salina Esmail","doi":"10.31038/edmj.2018233","DOIUrl":"https://doi.org/10.31038/edmj.2018233","url":null,"abstract":"Introduction/ Purpose: Decline in BMD following prednisone therapy is attributed to osteoporosis. However, osteomalacia due to low 125 OH Vitamin D and resulting hyperparathyroidism may also be contributors. Therefore, administration of 125 OH vitamin D3, Calcitriol on BMD was examined in subjects receiving chronic prednisone therapy and low BMD (T< 2.5) refractory to therapy with bisphosphanate, calcium and vitamin D3, Cholecalciferol. Methods: 21 subjects, ages 45–56 years receiving prednisone ≥3 years with declining BMD despite therapy with Cholecalciferol, CaCO3 and bisphosphanate were divided into 2 groups. Both groups continued Calcium and bisphosphanate. 10 subjects (group 1) received increased dose of Cholecalciferol, 2000 units daily while in 11 subjects (group 2), it was substituted by Calcitriol. Comprehensive metabolic panels (CMP) including serum calcium and alkaline phosphatase as well as 25 OH Vit D and 125 OH Vit D levels were determined every 6 months. BMD was determined at yearly interval. Results: CMP including calcium and phosphorus remained normal in both groups while alkaline phosphatase declined in group 2 alone. Serum 25 OH Vit D levels were subnormal (<20 pg/ml) in both groups and normalized (53 ±6 pg/ml) only in group 2. BMD continued to decline in group1 while improving (p<0.01) in group 2; BMD being significantly greater than group 1 (p<0.01). Conclusion: In subjects receiving chronic prednisone therapy, low BMD is induced by multiple mechanisms: osteomalacia caused by decreased 125 OH Vit D and osteoporosis caused by matrix collagen breakdown, hypogonadism and secondary hyperparathyroidism. Role of osteomalacia is confirmed by rising BMD on substituting active 125 OH vitamin D3, Calcitriol for inactive vitamin D3, Cholecalciferol.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46303848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. 糖尿病口服药物的持久性：A1c基线的时间和初级保健提供者使用的常见口服药物的回顾。

Endocrinology, diabetes and metabolism journal Pub Date : 2018-07-08 DOI: 10.31038/edmj.2018232

Lavanya Cherukuri, Michael S Smith, J. Tayek

{"title":"The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider.","authors":"Lavanya Cherukuri, Michael S Smith, J. Tayek","doi":"10.31038/edmj.2018232","DOIUrl":"https://doi.org/10.31038/edmj.2018232","url":null,"abstract":"Introduction\u0000Cost of generic medications has risen more in the past few years than any other time in history. While medical insurance covers much of these costs, health care professionals can better provide medications that have the longest duration of action when compared to placebo-treated controls. This will save health care costs and improve prescribing accuracy.\u0000\u0000\u0000Methods\u0000Papers in PubMed were identified with keywords placebo. The study must be at least 2 years in length to evaluate the change in A1c over time. The primary endpoint was time to A1c neutrality (return of A1c to baseline at a maximum dose of single oral agent). A medication would be considered at neutrality if the 95% CI crossed baseline. Time to neutrality was averaged for each medication within the class and each summarized for class effect.\u0000\u0000\u0000Results\u0000Effective therapy for the DPP-4 and sulfonylurea classes of medications are 3-4 years as compared to a 5-year time to A1c neutrality for metformin usage. In comparison, the projected time to A1c neutrality was approximately 6-8 years for rosiglitazone and pioglitazone. While only a few studies have been published in the SGLT-2 class of medication, the time to A1c neutrality was also 6-8 years with Canagliflozin and full dosage of Empagliflozin.\u0000\u0000\u0000Conclusion\u0000Metformin appears to have a 5-year duration of effect before the A1c returns to baseline. The sulfonylureas and DPP-4 inhibitors class of medications have one of the shortest durability which ranges between 3.3 to 4.4 years. In contrast, the SGLT-2 class of medication and the TZD class of medications has a projected time to A1c neutrality from 6-8 years. Diabetic duration of therapy as compared to placebo should be listed with those medications tested so the provider can choose wisely.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":"2 3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42390823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Higher Serum Ferritin in Tibetan and Han Populations with Diabetes Living on the Tibetan Plateau 青藏高原藏族和汉族糖尿病患者血清铁蛋白水平升高

Endocrinology, diabetes and metabolism journal Pub Date : 2018-01-01 DOI: 10.31038/edmj.2018211

Z. Bai, Chengyu Zhao, Shou Liu, Renjie Feng, S. Cui, R. Ge, D. McClain

{"title":"Higher Serum Ferritin in Tibetan and Han Populations with Diabetes Living on the Tibetan Plateau","authors":"Z. Bai, Chengyu Zhao, Shou Liu, Renjie Feng, S. Cui, R. Ge, D. McClain","doi":"10.31038/edmj.2018211","DOIUrl":"https://doi.org/10.31038/edmj.2018211","url":null,"abstract":"Objective: Tissue iron has emerged as a significant risk factor for diabetes. Pathways that sense and regulate iron and oxygen interact, but few studies examined the interactions of hypoxia and iron in determining diabetes risk in human populations. Accordingly, metabolic phenotyping with analysis of iron homeostasis in both Tibetan and Han Chinese living at 2300-3900m altitudes were conducted. Research design and methods: Data were collected on Tibetan and Han Chinese living at intermediate altitudes. Iron homeostatic and metabolic parameters including homeostasis model assessments (HOMA), hemoglobin A1c, serum ferritin and transferrin saturation were determined. Results: Serum ferritin is higher in both Tibetan groups compared to the respective Han groups, and higher in each diabetic group compared to nondiabetics of the same ethnicity. Serum iron and transferrin saturation were also higher in the Tibetan diabetics than the Tibetan non-diabetics. Serum iron was significantly correlated with ferritin levels in the four combined groups (r2=0.07313, p<0.05) and even stronger in the Tibetan diabetic group (r2=0.2702, p<0.05). HOMA-β was negatively correlated with ferritin in the Tibetan combined groups (r2=0.020, p<0.05), and HOMA-IR tended to be positively correlated with ferritin (r2=0.018, p<0.05). Conclusion: Iron parameters differ both between Han and Tibetans and between diabetics and nondiabetics of both populations. High ferritin, which in these cohorts reflects iron status, is a risk factor for diabetes in both groups, although how iron status relates to the diabetes phenotype differs between the two groups, possibly related to their differing histories of adaptation to high altitude.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69508954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases. 帕金森氏症和阿尔茨海默氏症患者与代谢综合征相关的外周色氨酸-犬尿氨酸代谢不同。

Endocrinology, diabetes and metabolism journal Pub Date : 2017-11-01 Epub Date: 2017-11-19

Gregory Oxenkrug, Marieke van der Hart, Julien Roeser, Paul Summergrad

{"title":"Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.","authors":"Gregory Oxenkrug, Marieke van der Hart, Julien Roeser, Paul Summergrad","doi":"","DOIUrl":"","url":null,"abstract":"Insulin resistance (IR), obesity and other components of metabolic syndrome [MetS] are highly associated with Alzheimer's (AD) and Parkinson's (PD) diseases. Dysregulation of kynurenine (Kyn) pathway (KP) of tryptophan (Trp) metabolism was suggested as major contributor to pathogenesis of AD and PD and MetS. KP, the major source of NAD+ in humans, occurs in brain and peripheral organs. Considering that some, but not all, peripherally originated derivatives of Kyn penetrate blood brain barrier, dysregulation of central and peripheral KP might have different functional impact. Up-regulated Kyn formation from Trp was discovered in central nervous system of AD and PD while assessments of peripheral KP in these diseases yield controversial results. We were interested to compare peripheral kynurenines in AD and PD with emphasis on MetS-associated kynurenines, i.e., kynurenic (KYNA) and anthranilic (ANA) acids and 3-hydroxykynurenine (3-HK). Serum concentrations of KP metabolites were evaluated (HPLC-MS method). In PD patients Trp concentrations were lower, and Kyn: Trp ratio, Kyn, ANA and KYNA were higher than in controls. 3-HK concentrations of PD patients were below the sensitivity threshold of the method. In AD patients. ANA serum concentrations were approximately 3 fold lower, and KYNA concentrations were approximately 40% higher than in controls. Our data suggest different patterns of KP dysregulation in PD and AD: systemic chronic subclinical inflammation activating central and peripheral KP in PD, and central, rather than peripheral, activation of KP in AD triggered by Aβ1-42. Dysregulation of peripheral KP in PD and AD patients might underline association between neurodegenerative diseases and MetS.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":"1 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747375/pdf/nihms927860.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35701297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adipose and Liver Function in Primate Offspring with Insulin Resistance Induced by Estrogen Deprivation in Utero. 子宫内雌激素剥夺致胰岛素抵抗灵长类后代的脂肪和肝功能。

Endocrinology, diabetes and metabolism journal Pub Date : 2017-08-01 Epub Date: 2017-09-12

Soon Ok Kim, Graham Aberdeen, Terrie J Lynch, Eugene D Albrecht, Gerald J Pepe

{"title":"Adipose and Liver Function in Primate Offspring with Insulin Resistance Induced by Estrogen Deprivation in Utero.","authors":"Soon Ok Kim, Graham Aberdeen, Terrie J Lynch, Eugene D Albrecht, Gerald J Pepe","doi":"","DOIUrl":"","url":null,"abstract":"Purpose: We recently demonstrated that offspring delivered to baboons deprived of estrogen during the second half of gestation exhibited insulin resistance. Therefore, because skeletal muscle accounts for >80% of insulin dependent glucose disposal, we suggested that estrogen in utero programs factors in fetal skeletal muscle important for insulin sensitivity in offspring. However, liver and adipose are also sites of insulin action and adipose insulin resistance can increase serum free fatty acid (FFA) levels and thereby reduce skeletal muscle insulin sensitivity. Therefore, in the current study we determined whether estrogen-deprived offspring exhibit normal adipose and hepatic function.Results: The fasting serum levels of adiponectin, leptin, glucose, and analytes of liver function as well as the basal levels of serum FFA were similar in offspring of estrogen replete/suppressed baboons. Moreover, the normal glucose-induced decline in serum FFA levels measured in untreated offspring was also measured in offspring of letrozole-treated baboons. Fetal serum levels of adiponectin and leptin in late gestation also were similar and expression of nitrotyrosine negligible in fetal liver and adipose of untreated and letrozole-treated animals.Conclusions: These results indicate that offspring of letrozole-treated baboons have normal adipose and liver function and do not exhibit adipose insulin resistance. Therefore, we suggest that the insulin resistance observed in estrogen-deprived offspring primarily reflects a decline in insulin-stimulated glucose clearance by skeletal muscle and which supports our original suggestion that estrogen in utero programs factors in fetal skeletal muscle that promote insulin sensitivity in offspring.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":"1 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035008/pdf/nihms-977363.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36293386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0